EFFECT OF RHEIN ON THE GLUCOSE-METABOLISM OF EHRLICH ASCITES TUMOR-CELLS

被引:26
作者
FLORIDI, A
CASTIGLIONE, S
BIANCHI, C
MANCINI, A
机构
[1] Laboratory of Cell Metabolism and Pharmacokinetics, Regina Elena Institute for Cancer Research, 00161 Rome
关键词
D O I
10.1016/0006-2952(90)90681-A
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of rhein, 4,5 dihydroxyanthraquinone-2-carboxylic acid, on oxygen consumption and the rate of aerobic and anaerobic lactate production by Ehrlich ascites tumor cells has been investigated. The rate of oxygen uptake decreases with the increase of rhein concentration. Rhein also inhibits aerobic and anaerobic glycolysis. The rate of aerobic lactate production decreases with the drug concentration and the maximal effect was observed at 0.100 mM. Anaerobic lactate production is also inhibited and the maximum effect is reached at 0.220 mM. The possibility that the lactate production decrease was secondary to an effect on mitochondrial ATPase was excluded on the basis of the data with DNP and oligomycin. Rhein reduces the intracellular level of lactate, pyruvate and glucose-6-phosphate. Glucose utilization and 2-deoxy-d-glucose uptake are decreased to the same extent as the inhibition of aerobic lactate production, whereas glucose phosphorylation is unaffected. It is, therefore, concluded that the inhibition of glycolysis of Ehrlich ascites tumor cells by rhein is caused by an impairment of glucose uptake. © 1990.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 46 条
  • [1] AISENBERG AC, 1961, GLYCOLYSIS RESPIRATI
  • [2] THE CELL BIOLOGY OF MULTIPLE-DRUG RESISTANCE
    BECK, WT
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (18) : 2879 - 2887
  • [3] INHIBITION OF LACTATE TRANSPORT AND GLYCOLYSIS IN EHRLICH ASCITES TUMOR-CELLS BY BIOFLAVONOIDS
    BELT, JA
    THOMAS, JA
    BUCHSBAUM, RN
    RACKER, E
    [J]. BIOCHEMISTRY, 1979, 18 (16) : 3506 - 3511
  • [4] MECHANISM OF MULTIDRUG RESISTANCE
    BRADLEY, G
    JURANKA, PF
    LING, V
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 948 (01) : 87 - 128
  • [5] BURK D, 1967, JNCI-J NATL CANCER I, V38, P839
  • [6] Bustamente E, 1977, Adv Exp Med Biol, V92, P363
  • [7] LONIDAMINE IN PRIMARY MALIGNANT BRAIN-TUMORS - PRELIMINARY-REPORT
    CARAPELLA, CM
    IANDOLO, B
    DELLECHIAIE, S
    RICCIO, A
    [J]. ONCOLOGY, 1984, 41 : 82 - 85
  • [8] THE POTENTIAL ROLE OF IONIDAMINE (LND) IN THE TREATMENT OF MALIGNANT GLIOMA - PHASE-II STUDY
    CARAPELLA, CM
    PAGGI, MG
    CATTANI, F
    CIOTTOLI, GB
    FLORIDI, A
    IANDOLO, B
    RAUS, L
    RICCIO, A
    CAPUTO, A
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1989, 7 (01) : 103 - 108
  • [9] CASTIGLIONE S, IN PRESS BIOCH PHARM
  • [10] Cori CF, 1925, J BIOL CHEM, V65, P397